Home › Companies › KYMERA THERAPEUTICS INC. › 2023-2024

KYMERA THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and KYMERA THERAPEUTICS INC.’s Form 8-K, filed 2024-06-20 (Item 5.07 on EDGAR). Page generated 04 October 2026.

6Ballot items
180Asset managers
1,551Fund votes
2024-06-18Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore KYMERA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by KYMERA THERAPEUTICS INC.

These tallies are KYMERA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-20 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

KYMERA THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-06-18
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Pamela Esposito, Ph.D.	49,219,482	--	--	6,587,819	1,855,694	Majority: yes
Elect Director: Gorjan Hrustanovic, Ph.D.	48,998,105	--	--	6,809,196	1,855,694	Majority: yes
Elect Director: Victor Sandor, M.D.C.M.	51,424,753	--	--	4,382,548	1,855,694	Majority: yes
Proposal 2: Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers	54,201,734	1,599,511	6,056	--	1,855,694	Majority: yes
Proposal 3: Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal yea	57,657,124	4,271	1,600	--	--	Majority: yes
Proposal 4: Approval of Amendment No	30,565,165	25,232,934	9,202	--	1,855,694	Majority: yes

Source: KYMERA THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-20 — read the filing on EDGAR.

How asset managers voted at the KYMERA THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 180 asset managers that disclosed a KYMERA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on a non-binding advisory basis, the compensation of our named executive officers;

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 9 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 54,201,734AGAINST: 1,599,511

KYMERA THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executi”): 54,201,734 for, 1,599,511 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,353,146 outstanding shares: 88% for, 3% against (91% of the company cast a for/against vote).

The 180 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 98%

FOR: 97.6%AGAINST: 2.4%ABSTAIN: 0.0%

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers;” at KYMERA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
T. Rowe Price	11,072,529	0	For
New York Life	11,013,572	0	For
Vanguard	7,260,505	0	For
Fidelity	6,726,271	0	For
BAKER BROS. ADVISORS LP	5,995,928	0	For
Atlas Venture Life Science Advisors, LLC	5,377,362	0	For
BVF INC/IL	5,161,801	0	For
Wellington	3,744,501	0	For
State Street	2,909,061	13,557	For
BlackRock	2,031,554	7,803	For
Avoro Capital Advisors LLC	1,891,243	0	For
Redmile Group, LLC	1,663,267	0	For
Rock Springs Capital Management LP	1,505,750	0	For
Charles Schwab	712,238	0	For
GEODE CAPITAL MANAGEMENT, LLC	579,979	0	For
JPMorgan	404,589	0	For
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	0	374,730	Against
MFS	0	346,166	Against
Candriam S.C.A.	0	328,291	Against
UBS	0	315,708	Against
Aquilo Capital Management, LLC	253,428	0	For
Hartford	208,495	0	For
Northern Trust	198,127	25	For
Deep Track Capital, LP	189,810	0	For
Neuberger Berman	187,641	0	For

Showing the 25 largest of 180 asset managers. See all 180 in the interactive database.

2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and

AUDIT-RELATEDMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 57,657,124AGAINST: 4,271

KYMERA THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered p”): 57,657,124 for, 4,271 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,353,146 outstanding shares: 94% for, 0.1% against (94% of the company cast a for/against vote).

The 69 asset managers below cast 100% of the shares they voted on this item FOR (19,528,500 for, 0 against).

FOR 99.9%

FOR: 19,528,500 (100.0%)ABSTAIN: 1,184 (0.0%)

Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fi” at KYMERA THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	7,141,763	0	For
T. Rowe Price	4,948,344	0	For
Fidelity	2,765,318	0	For
State Street	1,201,735	0	For
BlackRock	729,334	0	For
Charles Schwab	356,119	0	For
MFS	346,166	0	For
Hartford	208,495	0	For
JPMorgan	165,857	0	For
Direxion Shares ETF Trust	153,457	0	For
First Trust	135,718	0	For
Equitable	117,106	0	For
John Hancock	107,964	0	For
TIAA	95,162	0	For
Dimensional	90,702	0	For
AIG/SunAmerica	68,534	0	For
Northwestern Mutual	63,533	0	For
Neuberger Berman	62,543	0	For
Lincoln Financial	54,532	0	For
QUANTITATIVE MASTER SERIES LLC	52,703	0	For
Brighthouse	51,245	1,184	For
MML SERIES INVESTMENT FUND	52,081	0	For
American Century	48,165	0	For
Transamerica	47,121	0	For
ProShares	41,033	0	For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

3. TO APPROVE AN AMENDMENT TO THE KYMERA THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN.

COMPENSATIONMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

54.8% Majority: yes · of votes cast

FOR 54.8%AGAINST 45.2%

FOR: 30,565,165AGAINST: 25,232,934

KYMERA THERAPEUTICS INC.’s own tally for this item (“Proposal 4: Approval of Amendment No”): 30,565,165 for, 25,232,934 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,353,146 outstanding shares: 49.8% for, 41% against (91% of the company cast a for/against vote).

The 69 asset managers below cast 15% of the shares they voted on this item FOR (2,919,019 for, 16,575,774 against).

FOR 15%AGAINST 85%

FOR: 2,919,019 (15.0%)AGAINST: 16,575,774 (85.0%)ABSTAIN: 4,376 (0.0%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE KYMERA THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN.” at KYMERA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	2,433,390	4,708,373	0	Against
T. Rowe Price	0	4,948,344	0	Against
Fidelity	0	2,765,318	0	Against
State Street	1,255	1,200,480	0	Against
BlackRock	0	729,334	0	Against
Charles Schwab	0	356,119	0	Against
MFS	0	346,166	0	Against
Hartford	208,495	0	0	For
JPMorgan	0	165,857	0	Against
Direxion Shares ETF Trust	0	153,457	0	Against
First Trust	0	135,718	0	Against
Equitable	0	117,106	0	Against
John Hancock	45,332	62,632	0	Against
TIAA	0	95,162	0	Against
Dimensional	0	90,702	0	Against
AIG/SunAmerica	0	68,534	0	Against
Northwestern Mutual	63,533	0	0	For
Neuberger Berman	0	62,543	0	Against
Lincoln Financial	0	54,532	0	Against
QUANTITATIVE MASTER SERIES LLC	0	52,703	0	Against
Brighthouse	0	51,245	1,184	Against
MML SERIES INVESTMENT FUND	52,081	0	0	For
American Century	0	48,165	0	Against
Transamerica	0	47,121	0	Against
ProShares	0	41,033	0	Against

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

4. To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Gorjan Hrustanovic, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 48,998,105WITHHELD: 6,809,196

KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Gorjan Hrustanovic, Ph.D.”): 48,998,105 for, 6,809,196 withheld, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,353,146 outstanding shares: 80% for, 11% withheld (91% of the company cast a for/withheld vote).

The 68 asset managers below cast 100% of the shares they voted on this item FOR (16,166,074 for, 0 against).

FOR 83%ABSTAIN 17%

FOR: 16,166,074 (82.9%)ABSTAIN: 3,333,095 (17.1%)

Largest asset managers voting on “To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Sharehol” at KYMERA THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	7,141,763	0	For
T. Rowe Price	4,948,344	0	For
Fidelity	541,923	2,223,395	Abstain
State Street	1,200,030	1,705	For
BlackRock	729,334	0	For
Charles Schwab	356,119	0	For
MFS	0	346,166	Abstain
Hartford	208,495	0	For
JPMorgan	165,857	0	For
Direxion Shares ETF Trust	0	153,457	Abstain
First Trust	0	135,718	Abstain
Equitable	76,356	40,750	For
John Hancock	93,234	14,730	For
TIAA	95,162	0	For
Dimensional	0	90,702	Abstain
AIG/SunAmerica	0	68,534	Abstain
Northwestern Mutual	63,533	0	For
Neuberger Berman	62,543	0	For
Lincoln Financial	31,900	22,632	For
QUANTITATIVE MASTER SERIES LLC	52,703	0	For
Brighthouse	39,390	13,039	For
MML SERIES INVESTMENT FUND	52,081	0	For
American Century	0	48,165	Abstain
Transamerica	47,121	0	For
ProShares	0	41,033	Abstain

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

5. To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Pamela Esposito, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 49,219,482WITHHELD: 6,587,819

KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Pamela Esposito, Ph.D.”): 49,219,482 for, 6,587,819 withheld, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,353,146 outstanding shares: 80% for, 11% withheld (91% of the company cast a for/withheld vote).

The 68 asset managers below cast 100% of the shares they voted on this item FOR (16,167,644 for, 0 against).

FOR 83%ABSTAIN 17%

FOR: 16,167,644 (82.9%)ABSTAIN: 3,331,525 (17.1%)

Largest asset managers voting on “To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Sharehol” at KYMERA THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	7,141,763	0	For
T. Rowe Price	4,948,344	0	For
Fidelity	541,923	2,223,395	Abstain
State Street	1,200,030	1,705	For
BlackRock	729,334	0	For
Charles Schwab	356,119	0	For
MFS	0	346,166	Abstain
Hartford	208,495	0	For
JPMorgan	165,857	0	For
Direxion Shares ETF Trust	0	153,457	Abstain
First Trust	0	135,718	Abstain
Equitable	76,356	40,750	For
John Hancock	93,234	14,730	For
TIAA	95,162	0	For
Dimensional	0	90,702	Abstain
AIG/SunAmerica	0	68,534	Abstain
Northwestern Mutual	63,533	0	For
Neuberger Berman	62,543	0	For
Lincoln Financial	31,900	22,632	For
QUANTITATIVE MASTER SERIES LLC	52,703	0	For
Brighthouse	39,390	13,039	For
MML SERIES INVESTMENT FUND	52,081	0	For
American Century	0	48,165	Abstain
Transamerica	47,121	0	For
ProShares	0	41,033	Abstain

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

6. To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Victor Sandor, M.D.C.M.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 51,424,753WITHHELD: 4,382,548

KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Victor Sandor, M.D.C.M.”): 51,424,753 for, 4,382,548 withheld, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,353,146 outstanding shares: 84% for, 7% withheld (91% of the company cast a for/withheld vote).

The 68 asset managers below cast 100% of the shares they voted on this item FOR (17,123,050 for, 0 against).

FOR 88%12%

FOR: 17,123,050 (87.8%)ABSTAIN: 2,376,119 (12.2%)

Largest asset managers voting on “To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Sharehol” at KYMERA THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	7,141,763	0	For
T. Rowe Price	4,948,344	0	For
Fidelity	541,923	2,223,395	Abstain
State Street	1,201,605	130	For
BlackRock	729,334	0	For
Charles Schwab	356,119	0	For
MFS	346,166	0	For
Hartford	208,495	0	For
JPMorgan	165,857	0	For
Direxion Shares ETF Trust	153,457	0	For
First Trust	135,718	0	For
Equitable	76,356	40,750	For
John Hancock	107,964	0	For
TIAA	95,162	0	For
Dimensional	0	90,702	Abstain
AIG/SunAmerica	68,534	0	For
Northwestern Mutual	63,533	0	For
Neuberger Berman	62,543	0	For
Lincoln Financial	50,642	3,890	For
QUANTITATIVE MASTER SERIES LLC	52,703	0	For
Brighthouse	51,245	1,184	For
MML SERIES INVESTMENT FUND	52,081	0	For
American Century	48,165	0	For
Transamerica	47,121	0	For
ProShares	41,033	0	For

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

Largest KYMERA THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of KYMERA THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 61,353,146 shares outstanding at the time of that meeting.

Top KYMERA THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	T. Rowe Price	18.05%
2	New York Life	17.95%
3	Vanguard	11.83%
4	Fidelity	10.96%
5	BAKER BROS. ADVISORS LP	9.77%
6	Atlas Venture Life Science Advisors, LLC	8.76%
7	BVF INC/IL	8.41%
8	Wellington	6.10%
9	State Street	4.76%
10	BlackRock	3.32%

Reported KYMERA THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

KYMERA THERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
T. Rowe Price	10.32%	13F
Entities affiliated with BVF Partners L.P.	10.03%	DEF14A
Baker Bros. Advisors LP	9.78%	13D
Entities affiliated with Baker Bros. Advisors LP	9.78%	DEF14A
Felix Baker, Ph.D.	9.78%	DEF14A
FMR (Fidelity)	9.58%	13F
Vanguard Group	8.84%	13F
Entities affiliated with Atlas Venture Partners	8.76%	DEF14A
BlackRock	7.12%	13F
Wellington Management	7.00%	13F

Percentages above are of 61,353,146 shares outstanding, as reported by KYMERA THERAPEUTICS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KYMERA THERAPEUTICS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At KYMERA THERAPEUTICS INC.'s shareholder meeting held 2024-06-18, in the 2023-2024 proxy season, 180 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,551 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers; — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: KYMERA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-20.

KYMERA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.